These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25921268)

  • 21. Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.
    Hugenberg V; Behrends M; Wagner S; Hermann S; Schäfers M; Kolb HC; Szardenings K; Walsh JC; Gomez LF; Kopka K; Haufe G
    EJNMMI Radiopharm Chem; 2018 Dec; 3():10. PubMed ID: 30101186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.
    Yang SM; Scannevin RH; Wang B; Burke SL; Huang Z; Karnachi P; Wilson LJ; Rhodes KJ; Lagu B; Murray WV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1140-5. PubMed ID: 18083558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
    Nar H; Werle K; Bauer MM; Dollinger H; Jung B
    J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
    Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
    Hanessian S; MacKay DB; Moitessier N
    J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.
    Nuti E; Casalini F; Santamaria S; Gabelloni P; Bendinelli S; Da Pozzo E; Costa B; Marinelli L; La Pietra V; Novellino E; Margarida Bernardo M; Fridman R; Da Settimo F; Martini C; Rossello A
    Eur J Med Chem; 2011 Jul; 46(7):2617-29. PubMed ID: 21514700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix metalloproteinases.
    Faust A; Waschkau B; Waldeck J; Höltke C; Breyholz HJ; Wagner S; Kopka K; Schober O; Heindel W; Schäfers M; Bremer C
    Bioconjug Chem; 2009 May; 20(5):904-12. PubMed ID: 19374404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies.
    Wagner S; Breyholz HJ; Höltke C; Faust A; Schober O; Schäfers M; Kopka K
    Appl Radiat Isot; 2009 Apr; 67(4):606-10. PubMed ID: 19167232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First insight into structure-activity relationships of selective meprin β inhibitors.
    Ramsbeck D; Hamann A; Schlenzig D; Schilling S; Buchholz M
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2428-2431. PubMed ID: 28408220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability.
    Hugenberg V; Hermann S; Galla F; Schäfers M; Wünsch B; Kolb HC; Szardenings K; Lebedev A; Walsh JC; Mocharla VP; Gangadharmath UB; Kopka K; Wagner S
    Nucl Med Biol; 2016 Jul; 43(7):424-37. PubMed ID: 27179748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
    J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo.
    Schäfers M; Riemann B; Kopka K; Breyholz HJ; Wagner S; Schäfers KP; Law MP; Schober O; Levkau B
    Circulation; 2004 Jun; 109(21):2554-9. PubMed ID: 15123523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A highly soluble matrix metalloproteinase-9 inhibitor for potential treatment of dry eye syndrome.
    Mori M; De Lorenzo E; Torre E; Fragai M; Nativi C; Luchinat C; Arcangeli A
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):289-95. PubMed ID: 22520332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors.
    Nuti E; Cuffaro D; D'Andrea F; Rosalia L; Tepshi L; Fabbi M; Carbotti G; Ferrini S; Santamaria S; Camodeca C; Ciccone L; Orlandini E; Nencetti S; Stura EA; Dive V; Rossello A
    ChemMedChem; 2016 Aug; 11(15):1626-37. PubMed ID: 27356908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1.
    Zhang X; Gonnella NC; Koehn J; Pathak N; Ganu V; Melton R; Parker D; Hu SI; Nam KY
    J Mol Biol; 2000 Aug; 301(2):513-24. PubMed ID: 10926524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.
    Feng Y; Likos JJ; Zhu L; Woodward H; Munie G; McDonald JJ; Stevens AM; Howard CP; De Crescenzo GA; Welsch D; Shieh HS; Stallings WC
    Biochim Biophys Acta; 2002 Jul; 1598(1-2):10-23. PubMed ID: 12147339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2.
    Zhang W; Hou TJ; Qiao XB; Huai S; Xu XJ
    J Mol Model; 2004 Apr; 10(2):112-20. PubMed ID: 14986176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies.
    Ammazzalorso A; De Filippis B; Campestre C; Laghezza A; Marrone A; Amoroso R; Tortorella P; Agamennone M
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27782083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constructing and Validating 3D-pharmacophore Models to a Set of MMP-9 Inhibitors for Designing Novel Anti-melanoma Agents.
    Medeiros Turra K; Pineda Rivelli D; Berlanga de Moraes Barros S; Mesquita Pasqualoto KF
    Mol Inform; 2016 Jul; 35(6-7):238-52. PubMed ID: 27492238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.